Rubinstein & team report breakthrough gains in clinical trial

New data from Regeneron's Phase 1/2 CHORD trial is showing clinically meaningful improvements in hearing for nearly all children with profound genetic hearing loss caused by OTOF gene variants. In the latest results, 10 out of 11 children showed significant hearing gains, with speech and developmental progress already observed in the first child treated. These advancements are opening up life-changing possibilities, from enjoying music to participating in family activities.

Jay T. Rubinstein, MD, PhD, Virginia Merrill Bloedel Professor of Otolaryngology and Bioengineering and Director of the Bloedel Hearing Research Center at the University of Washington School of Medicine, a leading investigator in the trial, shared: “A child born profoundly deaf was able to enjoy music, engage in imaginative play, and participate in bedtime reading [after treatment].” 

This breakthrough highlights the potential of DB-OTO as a promising treatment for otoferlin-related hearing loss.

Special thanks to the incredible team at SeattleChildren's and key contributors: Meg Meredith, AuD, CCC-A, lead audiologist, and UW Oto research professor James O. Phillips, PhD, for their dedication to advancing hearing restoration!

For more details, read the article in GlobeNewswire.